Sherwin-Williams Co

SHW remains in a Stage 2 advancing regime with clear higher highs and higher lows and sustained above its rising EMAs. A pullback into the dynamic support of the 9 and 20 EMA zone on healthy volume offers a favorable entry aligned with the medium-term bullish bias. Execution is warranted now to participate in the ongoing uptrend on this structural repair.

• ↑Q1 2026 revenue $5.67B up 6.9% YoY; EPS $2.35 beat estimates.
• ↑Adjusted EBITDA grew 13.4% in Q4 2025; net debt/EBITDA 2.3×.
• ↓Weak earnings yield; management sees no help from market demand.